Protective Effects of Hyperoside on Type 2 Diabetes Through the Regulation of Pancreatic β‐cell Function
Immunity, Inflammation and Disease · 2026-07 · 14 (7)
DOI: 10.1002/iid3.70480 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 07.07.2026. Verfasst von Yuanyuan Jia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China. Hauptthemen laut MEDLINE: Quercetin, Insulin-Secreting Cells, Diabetes Mellitus, Type 2. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qiqihar City Science and Technology Bureau Joint Guidance Project.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Type 2 diabetes mellitus (T2D) is a prevalent chronic disease characterized by pancreatic β‐cell loss induced by hyperglycemia. Effective treatments to repair β‐cell damage remain unclear. Hyperoside, a flavonoid glycoside with diverse pharmacological effects, has rarely been studied in H 2 O 2 ‐induced β‐cell injury, and its mechanisms are unknown.
Objective
To explore the protective effects of hyperoside on H 2 O 2 ‐induced pancreatic β‐cell damage and its underlying mechanisms.
Methods
RIN‐m5F cells were pretreated with 0, 25, 50, 100 μM hyperoside or 5 μM ML385 (inhibitor of the Nrf2/HO‐1 pathway) for 48 h, followed by 100 μmol/ml H 2 O 2 for another 30 min. MTT assay and flow cytometry were used to assess cell viability and apoptotic cells. The activities of ROS, CAT, SOD, GSH‐PX, and MDA were measured using the corresponding assay kits. The levels of apoptosis‐related proteins, including cleaved‐caspase3 and caspase‐3, were determined by western blotting. A glucose‐stimulated insulin secretion (GSIS) assay was used to assess insulin secretion. Reverse‐transcription quantitative PCR (RT‐qPCR) and western blotting were used to measure the expression of Nrf2 and HO‐1 in the Nrf2/HO‐1 pathway.
Results
Hyperoside (0, 25, 50, 100 μM) showed no toxic side effects on RIN‐m5F cells. H 2 O 2 reduced RIN‐m5F cell viability, increased apoptosis, elevated ROS/MDA, decreased antioxidant enzyme activities, suppressed insulin secretion, and downregulated Nrf2/HO‐1. Hyperoside pretreatment reversed these effects, improving viability, reducing apoptosis, restoring antioxidant activity, enhancing insulin secretion, and upregulating Nrf2/HO‐1. ML385 abolished hyperoside's protective effects.
Conclusion
Hyperoside protects pancreatic β‐cells against oxidative stress and apoptosis by activating the Nrf2/HO‐1 pathway. It may serve as a potential therapeutic agent for preventing β‐cell damage in T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.
- Department of Nursing, Gannan County People's Hospital, Qiqihar, China.
ORCID-Profile: Fei Lin
Förderung
- Qiqihar City Science and Technology Bureau Joint Guidance Project
Zitieren
APA
Jia, Y., Ai, Y., & Lin, F. (2026). Protective Effects of Hyperoside on Type 2 Diabetes Through the Regulation of Pancreatic β‐cell Function. Immunity, Inflammation and Disease, 14(7). https://doi.org/10.1002/iid3.70480
Vancouver
Jia Y, Ai Y, Lin F. Protective Effects of Hyperoside on Type 2 Diabetes Through the Regulation of Pancreatic β‐cell Function. Immunity, Inflammation and Disease. 2026;14(7). doi:10.1002/iid3.70480
BibTeX
@article{Jia2026,
author = {Jia, Yuanyuan and Ai, Yincui and Lin, Fei},
title = {Protective Effects of Hyperoside on Type 2 Diabetes Through the Regulation of Pancreatic β‐cell Function},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {7},
doi = {10.1002/iid3.70480}
}
EUVIMED